UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

Frontiers in immunology, 2020-11, Vol.11, p.598877-598877

2020

Volltextzugriff (PDF)

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

Future oncology (London, England), 2020-05, Vol.16 (15), p.975-989

2020

Volltextzugriff (PDF)

HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development

Oncotarget, 2014-05, Vol.5 (10), p.2866-2880

2014

Volltextzugriff (PDF)

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211036544-17588359211036544

2021

Volltextzugriff (PDF)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

The New England journal of medicine, 2014-11, Vol.371 (20), p.1867-1876

2014

Volltextzugriff (PDF)

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

The lancet oncology, 2020-06, Vol.21 (6), p.808-820

2020

Volltextzugriff (PDF)

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial

JAMA oncology, 2017-05, Vol.3 (5), p.620

2017

Volltextzugriff (PDF)

Atezolizumab: an investigational agent for the treatment of biliary tract cancer

Expert opinion on investigational drugs, 2021-10, Vol.30 (10), p.1007-1015

2021

Volltextzugriff (PDF)

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework

Clinical pharmacology and therapeutics, 2023-09, Vol.114 (3), p.644-651

2023

Volltextzugriff (PDF)

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Journal of clinical oncology, 2024-10

2024

Volltextzugriff (PDF)

Serotonergic and Nonserotonergic Dorsal Raphe Neurons Are Pharmacologically and Electrophysiologically Heterogeneous

Journal of neurophysiology, 2004-12, Vol.92 (6), p.3532-3537

2004

Volltextzugriff (PDF)

Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro

Neuropharmacology, 2003-10, Vol.45 (5), p.575-584

2003

Volltextzugriff (PDF)

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

The oncologist (Dayton, Ohio), 2017-03, Vol.22 (3), p.264-271

2017

Volltextzugriff (PDF)

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.917-924

2015

Volltextzugriff (PDF)

On the Synchronizing Mechanisms of Tetanically Induced Hippocampal Oscillations

The Journal of neuroscience, 1999-09, Vol.19 (18), p.8104-8113

1999

Volltextzugriff (PDF)

Dynamic Modulation of Excitation and Inhibition During Stimulation at Gamma and Beta Frequencies in the CA1 Hippocampal Region

Journal of neurophysiology, 2001-06, Vol.85 (6), p.2412-2422

2001

Volltextzugriff (PDF)

Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment

The Journal of neuroscience, 2005-03, Vol.25 (12), p.3192-3198

2005

Volltextzugriff (PDF)

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

Clinical colorectal cancer, 2013-09, Vol.12 (3), p.218-222

2013

Volltextzugriff (PDF)

GABA Transporter Currents Activated by Protein Kinase A Excite Midbrain Neurons during Opioid Withdrawal

Neuron (Cambridge, Mass.), 2005-02, Vol.45 (3), p.433-445

2005

Volltextzugriff (PDF)

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia

Asia-Pacific journal of clinical oncology, 2013-09, Vol.9 (3), p.239-248

2013

Volltextzugriff (PDF)

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial – Authors' reply

The Lancet (British edition), 2024-08, Vol.404 (10453), p.657-658

2024

Volltextzugriff (PDF)

Cellular actions of opioids on periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR‐1

British journal of pharmacology, 2003-05, Vol.139 (2), p.362-367

2003

Volltextzugriff (PDF)

Adaptations in adenosine signaling in drug dependence: therapeutic implications

Critical reviews in neurobiology, 2003, Vol.15 (3-4), p.235-274

2003

Volltextzugriff (PDF)

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Journal of translational medicine, 2015-01, Vol.13 (Suppl 1), p.O4-O4

2015

Volltextzugriff (PDF)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

The New England journal of medicine, 2014, Vol.371 (20), p.1867-1876

2014

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(44)
Tagungsberichte
(1)

Sprache

Englisch
(44)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(33)
Humans
(20)
Male
(19)
Animals
(15)
Female
(11)
Biological And Medical Sciences
(10)
Adult
(9)
Medical Sciences
(9)
Oncology
(9)
Aged
(7)
Blood Coagulation - Drug Effects
(7)
Fibrinolysis - Drug Effects
(7)
Neurosciences & Neurology
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Middle Aged
(6)
Neurosciences
(6)
Action Potentials - Drug Effects
(5)
Double-Blind Method
(5)
Immunology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation

HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial

Atezolizumab: an investigational agent for the treatment of biliary tract cancer

Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Serotonergic and Nonserotonergic Dorsal Raphe Neurons Are Pharmacologically and Electrophysiologically Heterogeneous

Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro

A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

On the Synchronizing Mechanisms of Tetanically Induced Hippocampal Oscillations

Dynamic Modulation of Excitation and Inhibition During Stimulation at Gamma and Beta Frequencies in the CA1 Hippocampal Region

Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

GABA Transporter Currents Activated by Protein Kinase A Excite Midbrain Neurons during Opioid Withdrawal

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia

Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial – Authors' reply

Cellular actions of opioids on periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR‐1

Adaptations in adenosine signaling in drug dependence: therapeutic implications

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Suchergebnisse filtern